The Review on Antimicrobial Resistance (AMR) yesterday published its first paper, Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations.
Anatara has released its latest investor presentation to the Australian Securities Exchange.
Please click here to view the presentation.
BRISBANE, November 19, 2014: Anatara Lifesciences, a company developing non-antibiotic treatments for gastrointestinal diseases in animals and humans, has welcomed Antibiotic Awareness Week in Australia to increase awareness around the threat to human health of antibiotic resistance.
Antibiotic Awareness Week is part of a global initiative to raise awareness about antibiotic resistance and promote the responsible use of antibiotics. It urges that the “miracle” of antibiotics be preserved and warns that “no action today, no cure tomorrow”.
Overuse of antibiotics in humans and animals has led to bacteria developing resistance to medicines and becoming so-called “super bugs” that make illnesses harder to treat.
Around 80% of antibiotics in the US are used in animal production.
Anatara Lifesciences has developed a non-antibiotic therapy for diarrhoea called DetachTM that will help reduce the use of antibiotics in pigs.
“Antimicrobial resistance is a threat to human health that is increasingly becoming a major issue for authorities,” Anatara Chairman Mel Bridges said.
“Awareness is growing and with that will come demands from consumers, health authorities and farmers for non-antibiotic therapies for production animals.”
Detach™ works by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins, the underlying cause of diarrhoea. It works differently to antibiotics in that it doesn’t try to kill bacteria and instead lets them pass through the intestine harmlessly.
The Australian Commission on Safety and Quality in Health Care is working with key partners from human health, animal health and agriculture to raise awareness about the problem of antibiotic resistance.
Antibiotic Awareness Week is from November 17 to November 23.
Anatara has featured on one of Australia’s leading business television programs, Financial Review Sunday.
The program was about companies listing on the Australian Securities Exchange (ASX) in 2014 and included an interview with Anatara’s chief scientific officer and co-founder Dr Tracey Mynott.
Dr Mynott explained how stringent regulatory requirements necessary to list on the ASX validates the company and provides confidence to potential overseas partners.
To watch the video click here.
Anatara has released its first newsletter after successfully listing on the Australian Securities Exchange.
Please click here to view the newsletter.
Anatara Lifesciences is pleased to announce it has completed its first pilot manufacturing runs of Detach™ and will now initiate manufacture required for registration purposes under the Australian Pesticides and Veterinary Medicines Authority’s (AVPMA’s) product registration approval process.
Please click here to view the announcement.
Anatara Lifesciences has been added to the ASX’s Official List and it’s shares are due to commence trading on Thursday, October 16, 2014.
For more read here.
Anatara Lifescience’s impending listing on the Australian Securities Exchange has been discussed in the Float Watch section of Australia’s only daily broadsheet newspaper The Australian.
Analyst Tim Morris, from wise-owl.com, notes that the global appetite for pork is strong as Anatara develops Detach™, our non-antibiotic treatment for diarrhoea in pigs.
He says Anatara controls intellectual property associated with an earlier formulation of Detach™ and that Anatara has further developed the therapy in preparation for field trials.
Read more here.
BRISBANE, 7 October 2014: Anatara Lifesciences is pleased to announce it has raised $7 million through an oversubscribed Initial Public Offering that has now closed.
The company, which is developing non-antibiotic medicines for the treatment and prevention of diarrhoea in animals and humans, offered 14 million shares at $0.50 a share.
Anatara expects the shares to begin trading on the Australian Securities Exchange the week beginning October 13th, with the company opening with a market capitalisation of $18,875,000. The assigned ASX code is ANR.
“The response by investors to the offering has been fantastic,” Anatara Chairman and Co-Founder Dr Mel Bridges said.
“We look forward to delivering on the enthusiasm and faith investors have shown in supporting the company and its planned future. The fact that the lead compound is derived from pineapple stems, a natural and safe resource, and addresses a significant area of unmet medical need, seems to have resonated with investors,” Dr Bridges added.
Anatara’s lead product, DetachTM, is a non-antibiotic therapy to treat and prevent diarrhoea. The company is focused on commercialising DetachTM initially for use in pigs, ahead of expanding its use to other livestock, and then developing it for use in humans.
Health authorities around the world are moving to limit the use of antibiotics in animal production as their overuse contributes to the rise of antibiotic-resistant bacteria, so-called superbugs that threaten human health.
Anatara’s objectives include:
- Registration of DetachTM for use in pigs in Australia and the European Union
- Registration of DetachTM for use in pigs in the United States
- Development of DetachTM for humans
The IPO was led by Wilson HTM with co-manager Peloton Capital and legal advisers McCullough Robertson.
Anatara’s Chairman Mel Bridges conducted an interview recently with the Australian Associated Press which published an article that was widely reproduced across many media outlets.
The article highlighted that Anatara was raising $7 million in an initial public offering and would list on the Australian Securities Exchange.
It noted that Anatara’s lead product, DetachTM is a non-antibiotic medicine made from an extract from pineapple roots to treat and prevent diarrhoea in food production animals and planned to be first used in pigs.
US President Barack Obama has issued an Executive Order that aims to combat the rise of antibiotic resistant bacteria that represent a serious threat to public health and the economy.
It says the US Federal Government will work domestically and internationally to “detect, prevent, and control illness and death related to antibiotic-resistant infections by implementing measures that reduce the emergence and spread of antibiotic-resistant bacteria and help ensure the continued availability of effective therapeutics for the treatment of bacterial infections”.
Measures to tackle antimicrobial resistance include eliminating “the use of medically important classes of antibiotics for growth promotion purposes in food-producing animals”.
The Executive Order can be found here.
A report to the President on combating antibiotic resistance by the President’s Council of Advisors on Science and Technology can be found here.
The Anatara team met senior business journalist Tim Boreham from The Australian newspaper recently to brief him on Anatara and our plans. He notes we’re raising $7 million from investors and that we’re intending to conduct new trials to get Detach re-registered in Australia. He suggests people read our prospectus when it’s lodged.
Anatara’s chief scientific officer Dr Tracey Mynott was interviewed by ABC Radio Brisbane about how DetachTM was created and how treating diarrhoea in pigs could lead to treatments for humans.
To listen to the interview, click here.
By Dylan Bushell-Embling, Australian Life Scientist
Anatara Lifesciences used this week’s BIO International Convention to pursue distribution and development partners for Detach, its new non-antibiotic treatment for diarrhoea.
The company is pursuing commercialisation for the product in pigs first and subsequently plans to expand its use to other livestock and develop the treatment for use in humans.
Detach works by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins.
Anatara CEO Dr David Venables said there is a strong market opportunity for Detach in light of growing consumer demand for antibiotic-free food and concerns over antibiotic-resistant “superbugs”.
“The World Health Organization has warned that antimicrobial resistance is a significant looming threat to human health and authorities are now moving to tackle the issue by limiting the use of antibiotics in animal agriculture,” he said.
The article can be found here.
BRISBANE, June 24, 2014: Anatara Lifesciences, a company developing non-antibiotic treatments for gastrointestinal diseases in animals and humans, will be seeking distribution and development partners at the world’s largest biotechnology conference in the United States this week.
The company will be presenting at the 2014 BIO International Convention in San Diego and introducing to thousands of attendees its lead product Detach™, a non-antibiotic treatment for diarrhoea.
Anatara CEO Dr David Venables says the company is addressing a significant global problem around the rise of antimicrobial resistance and so-called “superbugs” caused by the overuse of antibiotics in production animals and humans.
“The World Health Organization has warned that antimicrobial resistance is a significant looming threat to human health and authorities are now moving to tackle the issue by limiting the use of antibiotics in animal agriculture,” Dr Venables says.
Anatara, which raised $1.75 million in a private placing earlier this year, is currently focused on commercialising Detach™ for use in pigs ahead of expanding its use to other livestock and then developing it for use in humans.
“Detach™ is a proven, natural treatment for diarrhoea in piglets and is an effective alternative to antibiotics,” Dr Venables says.
Anatara’s Chairman, life science industry veteran Mel Bridges, says that growing consumer demand for antibiotic-free food will make Detach™ an attractive product for livestock farmers.
“We have a unique value proposition to enter a market that’s worth billions of dollars every year,” he says.
Anatara Chief Science Officer Dr Tracey Mynott, who was one of the creators of Detach™, says the medicine works against bacteria, viruses and other causes of diarrhoea.
“Detach™ acts by stopping bacteria from attaching to the lining of the intestine, as well as blocking the action of their toxins, the underlying cause of diarrhoea. It works differently to antibiotics in that it doesn’t try to kill bacteria and instead lets them pass through the intestine harmlessly.”
While at the BIO International Convention, Anatara will seek partnering opportunities with animal health companies to distribute Detach™ around the world. It will also seek partners to develop the medicine for human use.
The United Kingdom’s Royal Pharmaceutical Society has recommended better stewardship in the use of antibiotics be encouraged in the wake of growing international concerns about the rise of antimicrobial resistance.
The recommendation is one of seven the society makes in a report discussing challenges around developing new medicines, improving existing medicines and making better use of the ones already available.
“The increasing development of resistance to currently available antibiotics is a potentially serious threat to public health,” the report, titled New Medicines, Better Medicines, Better Use of Medicines, says.
It says the “profound consequences of antibiotic resistance for individual patients and for society create an ethical and moral imperative to protect public health by all reasonable means”.
Two leaders in human health have called for the
creation of a global organisation to tackle the growing threat of
Mark Woolhouse, professor of infectious disease
epidemiology in the Centre for Immunity, Infection & Evolution at
the University of Edinburgh, and Jeremy Farrar, director of the global
health charity Wellcome Trust, have written in Nature seeking a
organisation similar to the Intergovernmental Panel on Climate Change.
“What is required is committed and coordinated action
on the root causes of resistance: the misuse of antimicrobials, the
paucity of development of new drugs and the lack of alternatives,”
“Guidelines must be implemented to improve the use of existing drugs;
the scientific and business worlds need incentives and a better
regulatory environment to develop new drugs and approaches, and those
working in both the animal and human sectors need education and
incentives to help them to change their ways.” Read more »
US regulators say 25 out of 26 drug makers that sell antibiotics used in livestock feed for growth enhancement have agreed to follow new guidelines that will make it illegal to use their products to create bigger animals. Read more »
The US Food and Drug Administration updates the animal pharmaceutical industry’s response to its plan to help phase out the use of medically important antimicrobials in food animals for food production purposes. Read more »
Lance Price is a public health researcher who works at the interface between science and policy to address the growing crisis of antibiotic resistance. To view his talk, delivered on March 11, 2014 in Manhattan, click here.
Policy-makers reacting the rise in bacteria resistant to antiobiotics.Read more »